S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
S&P 500   4,164.00 (+1.29%)
DOW   34,156.69 (+0.78%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
NASDAQ:ARWR

Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

$33.62
+0.11 (+0.33%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$32.06
$34.24
50-Day Range
$29.99
$40.56
52-Week Range
$26.81
$56.25
Volume
1.53 million shs
Average Volume
1.10 million shs
Market Capitalization
$3.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.22

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
81.6% Upside
$60.50 Price Target
Short Interest
Healthy
4.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
0.25mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$4.05 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.16) to ($2.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

131st out of 1,029 stocks

Pharmaceutical Preparations Industry

50th out of 504 stocks

ARWR stock logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Arrowhead Pharmaceuticals (ARWR) to Release Earnings on Monday
I Found a Good-Looking Arrowhead in This Biotech ETF
ARWR.C - | Stock Price & Latest News | Reuters
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
ARWR.MW - | Stock Price & Latest News | Reuters
ARWR: Sells Olpasiran Royalty Interest for $250 Million…
5 Top Biotech Stocks To Watch In July 2022
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings
2/06/2023
Today
2/07/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
329
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$60.50
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+76.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
10 Analysts

Profitability

Net Income
$-176,060,000.00
Pretax Margin
-71.01%

Debt

Sales & Book Value

Annual Sales
$243.23 million
Book Value
$3.95 per share

Miscellaneous

Free Float
101,372,000
Market Cap
$3.59 billion
Optionable
Optionable
Beta
1.02

Key Executives

  • Christopher Richard AnzaloneChristopher Richard Anzalone
    President, Chief Executive Officer & Director
  • Patrick C. O'brienPatrick C. O'brien
    COO, Secretary & Chief Compliance Officer
  • Kenneth Allen MyszkowskiKenneth Allen Myszkowski
    Chief Financial Officer
  • Javier San Martin
    Chief Medical Officer
  • Peter Carignan
    Vice President-Clinical Operations













ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2023?

10 Wall Street analysts have issued 1-year price objectives for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $31.00 to $90.00. On average, they predict the company's stock price to reach $60.50 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2023?

Arrowhead Pharmaceuticals' stock was trading at $40.56 on January 1st, 2023. Since then, ARWR shares have decreased by 18.4% and is now trading at $33.08.
View the best growth stocks for 2023 here
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings data on Monday, February, 6th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of $1.14 by $1.53. The biotechnology company earned $62.55 million during the quarter, compared to analysts' expectations of $162.52 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 40.23% and a negative net margin of 71.01%. The firm's quarterly revenue was up 127.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.60) earnings per share.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Western Financial Corp CA (0.77%), New York State Common Retirement Fund (0.33%), Retirement Systems of Alabama (0.31%), Privium Fund Management B.V. (0.21%), Banque Pictet & Cie SA (0.18%) and Wealth Effects LLC (0.15%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $33.08.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $3.53 billion and generates $243.23 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.68) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

The company employs 329 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 2/7/2023 by MarketBeat.com Staff